
Damora Therapeutics fell 1.6% from $22.85 to $22.50, behind the S&P 500's +11.2%. Its worst day was Dec 30 (−24.7%), and its low came Nov 24 at $16.31.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Damora Therapeutics closed at its lowest level of the year, 28.6% below where the year started.
−2.7% · S&P 500 +1.5%
Damora Therapeutics shares rose 24.5%, while the S&P 500 rose 0.1%.
+24.5% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Damora Therapeutics closed at its highest level of the year, 49.4% above where the year started.
+15.8% · S&P 500 0.0%
Damora Therapeutics shares rose 37.8%, while the S&P 500 fell 1.5%.
+37.8%, the year's best day · S&P 500 −1.5%
EPS of $2.90 beat the $-0.12 estimate on $0.00 revenue.
−5.5% · S&P 500 −1.4%
EPS of $-0.62 missed the $-0.56 estimate on $0.00 revenue.
+4.6% · S&P 500 +0.6%
EPS of $-0.39 missed the $-0.37 estimate on $0.00 revenue.
+2.8% · S&P 500 −0.3%
EPS of $-0.40 beat the $-0.45 estimate on $0.00 revenue.
−4.7% · S&P 500 −4.4%
Where it ended: a close of $22.50 on Nov 16, 2026.
Nothing in the past 12 months.
All DMRA dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DMRA and SPY from Benzinga historical bars. Not investment advice.